Citadel Advisors
DRUG

Citadel Advisors’s Bright Minds Biosciences DRUG Stock Holding History

Citadel Advisors’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,476
Closed -$393K – 12918
2025
Q3 		$393K Buy
+6,476
New +$251K ﹤0.01% 9709
2025
Q2 		– Sell
-6,885
Closed -$248K – 13069
2025
Q1 		$248K Buy
+6,885
New +$252K ﹤0.01% 10003
2024
Q2 		– Sell
-17,829
Closed -$21.4K – 14470
2024
Q1 		$21.4K Buy
+17,829
New +$31.3K ﹤0.01% 12968

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Citadel Advisors's DRUG Position: Q4 2025 in Review

Citadel Advisors sold out of Bright Minds Biosciences (DRUG) in Q4 2025, closing a stake of 6,476 shares — an estimated $393K sold.

Citadel Advisors first reported a position in DRUG in Q1 2024 and held it in 3 quarters. The position peaked at $393K in Q3 2025. 74 funds tracked by Wall St. Rank hold DRUG as of Q4 2025.

  • Citadel Advisors reported no remaining Bright Minds Biosciences position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 6,476 Bright Minds Biosciences shares in Q4 2025, an estimated $393K.
  • Citadel Advisors first reported a position in Bright Minds Biosciences in Q1 2024 and held it in 3 quarters.
  • Citadel Advisors's Bright Minds Biosciences position peaked at $393K in Q3 2025.
  • 74 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.